Bank of America’s AnaptysBio ANAB Stock Holding History

Bank of America’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-44,100	Closed	-$717K	–	6816
2019 Q4	$717K	Buy	+44,100	New	+$1.04M	﹤0.01%	4745

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America's ANAB Position: Q1 2026 in Review

Bank of America increased its AnaptysBio (ANAB) stake by 283% in Q1 2026, buying an estimated $19.9M and bringing the position to 501,086 shares worth $27.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2108.

Bank of America first reported a position in ANAB in Q1 2017 and has held it in 37 quarters since. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

Bank of America held 501,086 shares of AnaptysBio worth $27.8M as of Q1 2026.
Bank of America bought 370,319 AnaptysBio shares in Q1 2026, an estimated $19.9M.
AnaptysBio made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2108 holding.
Bank of America first reported a position in AnaptysBio in Q1 2017 and has held it in 37 quarters since.
207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.